Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tecemotide - Merck

Next Previous
Drug Profile

Tecemotide - Merck

Alternative Names: BLP25 liposomal vaccine; EMD-531444; Emepepimut-S; L-BLP25; LP-BLP-25; ONO-7165; Stimuvax

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomira
  • Developer EMD Serono; Merck KGaA; Merck Serono Co Ltd; National Cancer Institute (USA); Oncothyreon; Ono Pharmaceutical
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants; Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Rectal cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Mar 2018 Cascadian Therapeutics has been acquired by Seattle Genetics
  • 23 Feb 2018 Discontinued - Phase-II for Colorectal cancer in Austria, Belgium, Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top